BioSpace News Archive

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” or the “Company”) today reported financial results for the second quarter ended June 30, 2020 and provided an update on its business.

ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX), a clinical-stage biomedical company, today announced that due to the results that AAGP® has achieved over the previous years, we are now moving into whole organ transplantation, open heart surgery and cardiac ischemia treatment testing.

XPhyto Therapeutics Corp .a next generation bioscience company, is pleased to announce that its common shares are now trading on the OTCQB Venture Market (“OTCQB Venture”) under the stock symbol “XPHYF”.

Paragon 28, Inc., a leading orthopedic foot and ankle company, today announced the completion of a Series B financing.

Kalderos, the country’s first Drug Discount Manager, today announced it is now working with 3,000 340B covered entities through the Review tool in its Discount Monitoring solution, a revolutionary application that simplifies and streamlines collaboration on good faith inquiries for covered entities, ensuring compliance in the 340B Drug Pricing Program.

IDenta Corp. is a worldwide leader in the development of Field Detection and Home Diagnostics Testing Kits of Drugs & Explosives and Unique Forensic Products in the Homeland Security and Consumer Markets.

To support pediatricians, pharmacists and primary care physicians as schools reopen during the pandemic, MJH Life Sciences™ today announced it will host “Debating the Road Back to School,” a free, live, one-hour webinar on Thursday, Aug. 20, at 6 p.m. EDT.

Laser capture microdissection technology is a contamination free procedure for obtaining subpopulations of tissue cells under direct microscopic visualization.

The big data in healthcare market is believed to be the future and game-changer of the healthcare sector with high adoption amongst medical professionals, government bodies, and even patients.

Verona Pharma plc, a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces financial results for the three and six months ended June 30, 2020 and provides a corporate update.